370864-42-9

Basic information

• Product Name: tert-butyl 4-(3-cyanophenyl)-5,6-dihydropyridine-1(2H)-carboxylate
• Synonyms: tert-butyl 4-(3-cyanophenyl)-5,6-dihydropyridine-1(2H)-carboxylate;1(2H)-Pyridinecarboxylic acid, 4-(3-cyanophenyl)-3,6-dihydro-, 1,1-dimethylethyl ester
• CAS NO: 370864-42-9
• Molecular Formula: C₁₇H₂₀N₂O₂
• Molecular Weight: 284.3529
• Mol File: 370864-42-9.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: tert-butyl 4-(3-cyanophenyl)-5,6-dihydropyridine-1(2H)-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-(3-cyanophenyl)-5,6-dihydropyridine-1(2H)-carboxylate(370864-42-9)
• EPA Substance Registry System: tert-butyl 4-(3-cyanophenyl)-5,6-dihydropyridine-1(2H)-carboxylate(370864-42-9)

Safety Data

• Hazardous Substances Data: 370864-42-9(Hazardous Substances Data)

Upstream product

• 1386393-97-0 tert-butyl 4-[(1,1,2,2,3,3,4,4,4-nonafluorobutane-1-sulfonyl)oxy]-3,6-dihydropyridine-1(2H)-carboxylate 
• 150255-96-2 (3‐cyanophenyl)boronic acid 
• 6952-59-6 3-cyanobromobenzene 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 375853-96-6 4-(3-Cyano-phenyl)-4-hydroxy-piperidine-1-carboxylic acid-tert-butyl ester 
• 138647-49-1 4-Trifluoromethanesulfonyloxy-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 1290053-82-5 [3-(2-{4-[3-(aminomethyl)phenyl]piperidin-1-yl}-2-oxoethyl)phenyl]boronic acid 
• 1290056-55-1 tert-butyl 4-(3-((((benzyloxy)carbonyl)amino)methyl)phenyl)piperidine-1-carboxylate 
• 1290056-56-2 benzyl N-[[3-(4-piperidyl)phenyl]methyl]carbamate 
• 1290056-57-3 benzyl 3-(1-(2-(3,4-dihydroxyphenyl)acetyl)piperidin-4-yl)benzylcarbamate 
• 1290056-75-5 benzyl 3-(1-(2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetyl)piperidin-4-yl)benzylcarbamate 
• 1574730-95-2 3-(1-(2-(1,3-dioxoisoindolin-2-yl)ethyl)-1,2,3,6-tetrahydropyridin-4-yl)benzonitrile 
• 1574730-70-3 3-(1-(2-aminoethyl)-1,2,3,6-tetrahydropyridin-4-yl)benzonitrile 
• 1394387-86-0 3-(1-(2-((3-isopropylisoxazol-5-yl)methylamino)ethyl)-1,2,3,6-tetrahydropyridin-4-yl)benzonitrile 
• 370864-72-5 3-(piperidin-4-yl)-benzonitrile 
• 1290056-76-6 benzyl 3-(1-(2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetyl)piperidin-4-yl)benzylcarbamate 
• 1290053-74-5 1-(4-(3-(aminomethyl)phenyl)piperidin-1-yl)-2-(3,4-dihydroxyphenyl)ethanone hydrochloride 
• 1290056-54-0 tert-butyl 4-(3-(aminomethyl)phenyl)piperidine-1-carboxylate 
• 370864-73-6 tert-butyl 4-(3-cyanophenyl)piperidine-1-carboxylate 

Relevant articles and documents

SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION

The present invention covers aminoquinolone compounds of general formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8 and n are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase alpha regulated disorders, as a sole agent or in combination with other active ingredients.

Synthesis and biological evaluation of 1-(isoxazol-5-ylmethylaminoethyl)-4- phenyl tetrahydropyridine and piperidine derivatives as potent T-type calcium channel blockers with antinociceptive effect in a neuropathic pain model

New tetrahydropyridinyl and piperidinyl ethylamine derivatives were designed with hypothetical mapping on pharmacophore model generated from ligand-based virtual screening. The designed compounds were synthesized, and their inhibitory activities on T-type calcium channel were assayed using FDSS and patch-clamp assay. Among them, compounds 7b and 10b showed potent T-type calcium current blocking activity against Cav3.1 (α 1G) and Cav3.2 (α1H) channel simultaneously. With hERG and pharmacokinetics studies, compounds 7b and 10b were evaluated for the antinociceptive effect on rat model of neuropathic pain. They were significantly effective in decreasing the pain responses to mechanical and cold allodynia induced by spinal nerve ligation. These results suggest that modulation of α1G and α1H subtype T-type calcium channels may provide a promising approach for the treatment of neuropathic pain.

CHEMOKING RECEPTOR ANTAGONISTS

Disclosed herein are chemokine receptor antagonists of formula (I) wherein G1, X1, X2, and X3 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such compounds and compositions are also described.

COFERONS AND METHODS OF MAKING AND USING THEM

The present invention is directed to a monomer useful in preparing therapeutic compounds. The monomer includes one or more pharmacophores which potentially binds to a target molecule with a dissociation constant of less than 300 μM and a linker element connected to the pharmacophore. The linker element has a molecular weight less than 500 daltons, is connected, directly or indirectly through a connector, to the pharmacophore.

BENZOXAZINYL-AMIDOCYCLOPENTYL-HETEROCYCLIC MODULATORS OF CHEMOKINE RECEPTORS

Cyclopentyl compounds linked to a benzoxazinyl group through an amido moiety utilizing the ring nitrogen of the benzoxazine, and further substituted with a heterocyclic moiety, such compounds represented by formula I: which are used to modulate the CCR-2 chemokine receptor to prevent or treat inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis; and pharmaceutical compositions comprising these compounds and the use of these compounds and compositions.

Structure based design of 4-(3-aminomethylphenyl)piperidinyl-1-amides: Novel, potent, selective, and orally bioavailable inhibitors of βII tryptase

Tryptase is a serine protease found almost exclusively in mast cells. It has trypsin-like specificity, favoring cleavage of substrates with an arginine (or lysine) at the P1 position, and has optimal catalytic activity at neutral pH. Current evidence suggests tryptase β is the most important form released during mast cell activation in allergic diseases. It is shown to have numerous pro-inflammatory cellular activities in vitro, and in animal models tryptase provokes broncho-constriction and induces a cellular inflammatory infiltrate characteristic of human asthma. Screening of in-house inhibitors of factor Xa (a closely related serine protease) identified β-amidoester benzamidines as potent inhibitors of recombinant human βII tryptase. X-ray structure driven template modification and exchange of the benzamidine to optimize potency and pharmacokinetic properties gave selective, potent and orally bioavailable 4-(3-aminomethyl phenyl)piperidinyl-1-amides.

BENZOXAZINYL-AMIDOCYCLOPENTYL-HETEROCYCLIC MODULATORS OF CHEMOKINE RECEPTORS

Cyclopentyl compounds linked to a benzoxazinyl group through an amido moiety utilizing the ring nitrogen of the benzoxazine, and further substituted with a heterocyclic moiety, such compounds represented by formula (I): which are used to modulate the CCR-